EPOWUS: Pregnant Obese Women and Fetal Ultrasound Quality.

Sponsor
University Hospital, Clermont-Ferrand (Other)
Overall Status
Unknown status
CT.gov ID
NCT04212234
Collaborator
(none)
640
5
2
21
128
6.1

Study Details

Study Description

Brief Summary

Ultrasound (US) image construction uses equations that contain the value of the propagation velocity of sound waves; this velocity is assumed conventionally to be constant and equal to 1540 m/s in the human body. Since 1977, all manufacturers of US scanners have used this value, which was first established in 1950. In fatty tissue, however, the actual propagation velocity is only in the order of 1450 m/s. US velocity in fat tissue is slower than in other soft tissues (ie:1450 m/s vs 1540 m/s) therefore the intrinsic image quality in terms of sharpness and precision is improved when considering this parameter for image construction The main objective of this study is to evaluate the impact of ultrasound propagation velocity setting on completeness of ultrasound exams and images quality during the second and third trimester fetal ultrasound examination in obese patients.

Condition or Disease Intervention/Treatment Phase
  • Device: ultrasound propagation velocities, ultrasound fetal quality
N/A

Detailed Description

Obese pregnant women will be included before the second trimester fetal ultrasound examination.

Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam.

In the control group, exam will be performed using the conventional ultrasound velocity.

An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached.

The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline.

All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
640 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Scans will be evaluated by independent experts who had not performed the exams. Scans will be anonymized and ultrasound propagation velocity will not be reported on the images.
Primary Purpose:
Diagnostic
Official Title:
Echography in Pregnant Obese Women and Ultrasound Speed.
Actual Study Start Date :
Dec 2, 2019
Anticipated Primary Completion Date :
Mar 1, 2021
Anticipated Study Completion Date :
Sep 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: free ultrasound propagation velocity

ultrasound exams will be performed using several ultrasound propagation velocities

Device: ultrasound propagation velocities, ultrasound fetal quality
Obese pregnant women will be included before the second trimester fetal ultrasound examination. Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam. In the control group, exam will be performed using the conventional ultrasound velocity. An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached. The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline. All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al.

No Intervention: conventional ultrasound propagation velocity

ultrasound exams will be performed using the 1540m/s conventional celerity

Outcome Measures

Primary Outcome Measures

  1. image quality of fetal ultrasound exam [second trimester and third trimester ultrasound exam]

    Quality will be assessed by calculating Salomon's score for each image.

  2. completeness of fetal ultrasound exam [second trimester and third trimester ultrasound exam]

    completeness will be assessed by the number of the recommended images which could have been registered during the first ultrasound exam in each trimester.

Secondary Outcome Measures

  1. use of supplementary ultrasound exams in order to assess completeness [through study completion, an average of 1 year]

    description of each modality of supplemental ultrasound exam

  2. description of ultrasonographist method in order to improve ultrasound exam [through study completion, an average of 1 year]

    description of modality

  3. economic analysis of the intervention [through study completion, an average of 1 year]

    cost-effectiveness analysis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Body mass index>30

  • Between 20 and 25 weeks of gestation

Exclusion Criteria:
  • Multiple pregnancy

  • Uterine scare

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Estaing - Centre Hospitalier Universitaire de Clermont-Ferrand Clermont-Ferrand France 63000
2 Hôpital de la Croix Rousse - Hospices Civils de Lyon Lyon France
3 Hôpital Femme Mére Enfant - Hospices Civils de Lyon Lyon France
4 Hôpital Arnaud de Villeneuve - CHU de Montpellier Montpellier France
5 Hôpital Cochin - Assistance Publique - Hôpitaux de Paris Paris France

Sponsors and Collaborators

  • University Hospital, Clermont-Ferrand

Investigators

  • Principal Investigator: Amélie Delabaere, MD, PhD, CHU de Clermont-Ferrand

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT04212234
Other Study ID Numbers:
  • PHRC IR 2018 DELABAERE
  • 2018-A03478-47
First Posted:
Dec 26, 2019
Last Update Posted:
Jan 21, 2020
Last Verified:
Dec 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Clermont-Ferrand
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 21, 2020